GlobeNewswire

Mandalay Resources Corporation Announces Production and Sales Results for the First Quarter 2018

Dela

TORONTO, April 12, 2018 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX:MND) announced today its production and sales results for the first quarter of 2018.

In the first quarter of 2018, Mandalay produced a consolidated 23,172 saleable ounces of gold equivalent and sold 29,151 ounces of gold equivalent.

Mark Sander, President and Chief Executive Officer of Mandalay, commented, "Mandalay's production and sales results for the first quarter of 2018 place us firmly on track to reach our 2018 production guidance of 101,000 to 113,000 gold equivalent ounces."

Dr. Sander continued, "Björkdal produced 12,716 ounces of gold in the first quarter of 2018, about 20% higher than the comparative year-ago quarter. Also in the current quarter, Björkdal recorded the second highest sales under Mandalay ownership at 17,677 gold ounces. This occurred as inventory from the record fourth quarter 2017 production was sold. Follow-on revenue due to the high sales volume in the first quarter will strengthen our cash position."

Dr. Sander concluded, "Costerfield produced 10,456 gold equivalent ounces in the first quarter of 2018. First quarter production was comparatively lower than in the previous year quarter due to expected lower mining grades.  We are on track with respect to the capital development program, announced in November 2017, to reach the Brunswick Lode, which we expect will open up additional production fronts and extend mine life. Simultaneously, we are aggressively continuing infill and extensional drilling in the recently announced Youle vein target, for which we released some very encouraging high-grade intercepts earlier this April (see Mandalay April 3, 2018 press release)."

Saleable production for the three months ended March 31, 2018:

  • The Company produced a total of 19,303 ounces of gold and 605 tonnes of antimony, representing a total of 23,172 ounces of gold equivalent in the first quarter of 2018, versus 21,370 ounces of gold, 741 tonnes of antimony and 435,076 ounces of silver, representing a total of 32,481 ounces of gold equivalent in the first quarter of 2017 when Cerro Bayo was operating. 
     
  • The Björkdal mine (Sweden) produced 12,716 ounces of gold in the first quarter of 2018, as compared to 10,648 ounces of gold in the first quarter of 2017.
     
  • The Costerfield mine (Australia) produced 6,587 ounces of gold and 605 tonnes of antimony in the first quarter of 2018, versus 7,987 ounces of gold and 741 tonnes of antimony in the first quarter of 2017. 
     
  • The Cerro Bayo mine (Chile) produced no metal in the first quarter of 2018 because it remains on care and maintenance due to the inundation event of June 2017. By comparison, in the previous year first quarter, it produced 435,076 ounces of silver and 2,735 ounces of gold.

Table 1 - Saleable Production for the First Quarter 2018 and 2017, and Fourth Quarter 2017

Metal Source Three months
ended 

31 March
2018
Three months
ended 

31 March
2017
Three months
ended

31 December
2017
Gold (oz) Björkdal 12,716 10,648 22,035
  Costerfield 6,587 7,987 7,222
  Cerro Bayo - 2,735 -
  Total 19,303 21,370 29,257
Antimony (t) Costerfield 605 741 805
Silver (oz) Cerro Bayo - 435,076 -
Average quarterly prices:        
Gold US$/oz   1,329 1,217 1,275
Antimony US$/t   8,499 8,058 8,137
Silver US$/oz   16.77 17.36 16.71
Au Eq. (oz)1 Björkdal 12,716   10,648 22,035
  Costerfield 10,456 12,891  12,360
  Cerro Bayo - 8,942 -
  Total 23,172 32,481 34,395

1  Quarterly gold equivalent ounces ("Au Eq. oz") produced is calculated by multiplying the saleable quantities of gold ("Au"), silver ("Ag"), and antimony ("Sb") in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au in the period.  Average Au price in the period is calculated as the average of the daily LME PM fixes in the period, with price on weekend days and holidays taken of the last business day; average Sb price in the period is calculated as the average of the daily average of the high and low Rotterdam warehouse prices for all days in the period, with price on weekend days and holidays taken from the last business day; average Ag price in the period is calculated as the average of the daily London Broker's silver spot price for all days in the period, with price on weekend days and holidays taken from the last business day. The source for all prices is www.metalbulletin.com.

Sales for the three months ended March 31, 2018:

  • The Company sold 24,808 ounces of gold and 679 tonnes of antimony, representing a total of 29,151 ounces of gold equivalent in the first quarter of 2018, versus 23,668 ounces of gold, 708 tonnes of antimony, and 451,777 ounces of silver, representing a total of 34,801 ounces of gold equivalent in the first quarter of 2017 when Cerro Bayo was operating.
     
  • Björkdal sold 17,677 ounces of gold in the first quarter of 2018, versus 13,121 ounces of gold in the first quarter of 2017.
     
  • Costerfield sold 7,131 ounces of gold and 679 tonnes of antimony in the first quarter of 2018, versus 7,547 ounces of gold and 708 tonnes of antimony in the first quarter of 2017.
     
  • Cerro Bayo sold nothing in the first quarter of 2018, as production has been suspended since June 2017.

Table 2 - Sales for the First Quarter 2018 and 2017, and Fourth Quarter 2017

Metal Source Three months
ended 

31 March
2018
Three months
ended 

31 March
2017
Three months
ended

31 December
2017
Gold (oz) Björkdal 17,677 13,121 18,565
  Costerfield 7,131 7,547 6,337
  Cerro Bayo - 3,000 142
  Total 24,808 23,668 25,044
Antimony (t) Costerfield 679 708 668
Silver (oz) Cerro Bayo - 451,777 18,334
Average quarterly prices:        
Gold US$/oz   1,329 1,217 1,275
Antimony US$/t   8,499 8,058 8,137
Silver US$/oz   16.77 17.36 16.71
Au Eq. (oz)1 Björkdal 17,677 13,121 18,565
  Costerfield 11,474 12,235  10,599
  Cerro Bayo - 9,445 383
  Total 29,151 34,801 29,547

1 Quarterly Au Eq. oz sold is calculated by multiplying the saleable quantities of Au, Ag, and Sb in the period by the respective average market prices of the commodities in the period, adding the three amounts to get a "total contained value based on market price", and then dividing that total contained value by the average market price of Au for the period. The source for all prices is www.metalbulletin.com with price on weekend days and holidays taken of the last business day.

For Further Information:

Mark Sander
President and Chief Executive Officer

Greg DiTomaso
Director of Investor Relations

Contact: 
647.260.1566

About Mandalay Resources Corporation:

Mandalay Resources is a Canadian-based natural resource company with producing assets in Australia and Sweden, and care and maintenance and development projects in Chile. The Company is focused on executing a roll-up strategy, creating critical mass by aggregating advanced or in production gold, copper, silver and antimony projects in Australia, the Americas and Europe to generate near-term cash flow and shareholder value.

Forward-Looking Statements:

This news release contains "forward-looking statements" within the meaning of applicable securities laws, including statements regarding the Company's production of gold, silver and antimony for the 2018 fiscal year. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, changes in commodity prices and general market and economic conditions. The factors identified above are not intended to represent a complete list of the factors that could affect Mandalay. A description of additional risks that could result in actual results and developments differing from those contemplated by forward-looking statements in this news release can be found under the heading "Risk Factors" in Mandalay's annual information form dated March 29, 2018, a copy of which is available under Mandalay's profile at www.sedar.com. In addition, there can be no assurance that any inferred resources that are discovered as a result of additional drilling will ever be upgraded to proven or probable reserves. Although Mandalay has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Mandalay Resources Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum